New obesity drug tested in china for first time
NCT ID NCT06352892
Summary
This early-stage study tested a single injection of an experimental drug called AMG 133 (Maridebart Cafraglutide) in 20 Chinese adults who have obesity or are overweight. The main goals were to see how the body processes the drug and to check for any side effects. This is the first step to see if the drug is safe enough for larger studies that would test if it helps with weight management.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Queen Mary Hospital
Hong Kong, 000, Hong Kong
Conditions
Explore the condition pages connected to this study.